Navigation Links
Boston Scientific Announces Launch of Expanded Size Range of FilterWire EZ(TM) Embolic Protection System
Date:5/19/2008

s, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward- looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.


'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientific Announces FDA Approval of New Heart Failure Lead
2. Boston Scientifics SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)
3. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
4. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
5. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
6. Fraunhofer and Boston University Hosted Prestigious SME Tour
7. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
8. Boston Scientific Announces Results for First Quarter Ended March 31, 2008
9. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
10. Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System
11. Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 Report Details ... highest potential revenues Do you want to find ... you revenue predictions for those biological drugs from ... you find financial data, R&D trends, opportunities and ... sales forecasts to 2024 at overall world market, ...
(Date:9/30/2014)... 2014 Proove Biosciences , the ... to announce a new genetic test built upon research ... Perception Test will provide physicians with an objective ... tolerance levels are stratified between individuals. With this new ... person has a genetic predisposition that will affect their ...
(Date:9/30/2014)... , September 30, 2014 ... intuitive browsing of chemistry in documents ... software solutions and consulting services for life science ... information and generate Markush structures from documents. ... organizations intellectual property, however generating and understanding Markush ...
(Date:9/30/2014)... Sept. 30, 2014 BioHealth Innovation, Inc. ... market-relevant biohealth innovations and increasing access to early-stage funding ... that venture capitalist, Tania Fernandez , Ph.D., has ... Fernandez will be a member of the management team ... up to $50 million in seed and early-stage equity ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... Group,plc (AIM: PRG) announces the appointment of Melissa ... will be,responsible for leading the International Business Development ... business development position within,Kendle International leading a Global ... within business development in the CRO sector with ...
... Quigley,Corporation (Nasdaq: QGLY ) today issued an update ... Peripheral Neuropathy by its wholly owned,subsidiary, Quigley Pharma, ... that over 100 subjects have been,enrolled, 52 subjects have ... the Phase IIB study designed to evaluate the safety ...
... Will Begin Promotion in October At U.S. Psychiatric ... Pharmaceuticals,Inc. announced today that it has acquired the ... from Shire,plc. EQUETRO(R) is a treatment for ... Disorder -- a condition where patients experience,extended periods ...
Cached Biology Technology:Premier Research Appoints Melissa Jones as Vice President, International Business Development 2Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy 2Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy 3Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R) 2
(Date:9/30/2014)... marijuana, new research, involving mice and published in the ... Leukocyte Biology , suggests that just because you ... because a team of Italian scientists have found that ... to the immune system. This damage may result in ... sclerosis, inflammatory bowel disease and rheumatoid arthritis in adulthood. ...
(Date:9/30/2014)... 2014  Spectra Automation, a trusted supplier ... and power generation industries, announced today the ... an easy-to-use and cost-effective data collection, analysis ... laboratories. Most upstream process ... systems. Accessing and consolidating data from these ...
(Date:9/29/2014)... the exposure to tar tended to be lower for ... Similarly, exposure to nicotine tended to be lower. , ... in several countries around the world. Previous studies have ... the smoke of these cigarettes are lower than those ... in the smoke are not necessarily linked to a ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2Slim cigarette smokers not exposed to more harmful chemicals 2
... resistant to Crown Rot a disease that costs Australian ... year. Crown Rot, which is a chronic problem throughout ... Fusarium . Dr Chunji Liu and his CSIRO Plant ... scan over 2400 wheat lines and 1000 barley lines from ...
... 27, 2009 -- Worldwide demand for a safe and ... the forefront of sustainability discussions; however many research programs ... of traditional public or formula grants. Researchers are now ... and international plant breeding programs. Stakeholders from public ...
... Oregon State University researchers shows that those in poverty in ... be eating, but face tough choices between eating well and ... Rosenberger, both professors of anthropology at OSU, examined the "double ... interviews with 76 low-income households in two rural Benton County ...
Cached Biology News:How do we fund plant breeding? 2How do we fund plant breeding? 3Poor in rural Oregon face 'double binds' when getting food 2Poor in rural Oregon face 'double binds' when getting food 3
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Goat polyclonal to HA1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: TLGSCRERQPEFV from the C terminus of human HA1. Entrez GeneID: 23526 Swiss Protein ID: O78181...
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Biology Products: